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CORRESPONDENCE
Re: Discrete Alterations in
the BZLF1 Promoter in Tumor
and Non-Tumor-Associated
Epstein–Barr Virus
In their recent article, Gutie´rrez et al.
(1) identified three Epstein–Barr virus
(EBV) variants in the BZLF1 promoter
Zp (Zp-P [considered the prototypical
sequence], Zp-V3, and Zp-V4) and pos-
tulated that these might result in differ-
ent lytic potentials and be differentially
expressed among individuals with non-
malignant and malignant diseases. Hong
Kong and Southern China are consid-
ered to be endemic regions, with the
EBV variants that are different from
other localities.
We analyzed EBV type and sequence
variations in EBV Zp domains by direct
DNA sequencing in a total of 95 EBV-
associated lesions (96 isolates) from in-
dividuals from Hong Kong and South-
ern China (Table 1). Eighty-seven of 95
(91.6%) lesions contained type A EBV.
Eight (8.4%) lesions contained type B
EBV, all of which carried Zp-V3. Of the
88 type A EBV isolates, 31 (35.2%)
contained Zp-P and 53 (60.2%) con-
tained Zp-V3. From 36 nonmalignant
samples with type A EBV, 19 (52.8%)
contained Zp-P, and 16 (44%) contained
Zp-V3. From 51 malignant samples, we
obtained 52 EBV isolates with type A
EBV, of which 12 (23.1%) contained
Zp-P and 37 (71.2%) contained Zp-V3.
In addition, from one nonmalignant and
three malignant samples with type A
EBV, we identified four novel Zp-P
variants. Three variants differed from
Zp-P at one position only: Zp-V1_104
(–104C-A), isolated from a healthy car-
rier; Zp-V1_105 (–105C-T), isolated
from a natural killer (NK)/T-cell lym-
phoma; and Zp-V1_119 (–119G-A), iso-
lated from a nasopharyngeal carcinoma
(NPC). All these substitutions occurred
within the ZIIIB domain of Zp, which
can strongly bind ZEBRA (Z, EB repli-
cation activator) and contribute to the
transactivation of Zp (2). A fourth vari-
ant (Zp-V3+118), isolated from an NPC,
contained four nucleotide substitutions
relative to Zp-P, three of which were
identical to those found in Zp-V3 (1),
and the fourth a C to T substitution at
position –118. This position is also
within the functional domain of ZIIIB. It
is noteworthy that this variant with four
nucleotide substitutions was different
from the Zp-V4 variant described by
Gutie´rrez et al. (1). Taken together,
these results suggest that the ZIIIB do-
main may be a mutational hotspot.
It was suggested that only Zp-P and
Zp-V4, but not Zp-V3, were found in
the nonmalignant samples (1). However,
in the 40 nonmalignant samples from
our locality, Zp-P and Zp-V3 occurred
with similar frequency (19 of 40 and 20
of 40, respectively). None of our 95
samples contained Zp-V4, suggesting
that the Zp-V4 identified by Gutierrez´
et al. (1) may be restricted to people in a
particular geographic region. In our ma-
lignant NPC samples, 80.5% (33/41)
contained Zp-V3 and 14.6% (6/41) con-
tained Zp-P, whereas in the nonmalig-
nant samples, 50% (20/40) contained
Zp-V3 and 47.5% (19/40) contained
Zp-P. Thus, Zp-V3 was more prevalent
in NPC samples than in nonmalignant
samples (P  .001, chi-square test). If
we considered only type A EBV iso-
lates, then the association between NPC
and Zp-V3 was still statistically signifi-
cant (P  .001).
In our locality, the distribution of
EBV variants with respect to Zp in
various EBV-associated conditions is
distinct from other geographic regions.
Although Zp-V3 is detectable in nonma-
lignant samples, it is statistically signifi-
cantly associated with NPC. Whether
these variants have a functional con-
sequence remains to be determined.
However, the possible link(s) between
different variants and lytic potential or
latency-to-lytic cycle switch requires
further investigation.
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Table 1. Distribution of BZLF1 promoter variants in type A and type B Epstein–Barr virus (EBV)
isolates from healthy carriers and various EBV-associated conditions*
Total Zp-P Zp-V3 Zp-V3+118 Zp-V1
Type A EBV
Non-malignant
HC 21 11 9 0 1
IM 15 8 7 0 0
Total 36 19 16 0 1
Malignant
NPC† 37 6 29 1 1
NK/T 12 6 5 0 1‡
PTLD 3 0 3 0 0
Total 52 12 37 1 2
Type B EBV
Non-malignant
HC 3 3
IM 1 1
Total 4 4
Malignant
NPC 4 4
Total 4 4
*A total of 96 EBV isolates from 40 non-malignant samples and 55 malignant samples were analyzed
by direct sequencing. Briefly, amplification of position −221 to +12 (with reference to the transcription
start site) of the BZLF1 promoter region was performed by using the polymerase chain reaction (PCR) as
described by Gutie´rrez et al. (1). Purified PCR products were sequenced using ABI PRISM Big Dye
terminator cycle sequencing Kit (Applied Biosystems, Foster City, CA), and the sequencing products were
run on an ABI 377 DNA auto-sequencer (Applied Biosystems). The non-malignant samples included 24
gargle specimens collected by rinsing the mouth with phosphate-buffered saline from healthy donors who
were EBV carriers (HC) and 16 peripheral blood samples from subjects with infectious mononucleosis
(IM). The malignant samples included biopsies of 39 nasopharyngeal carcinomas (NPC), 11 natural killer
(NK)/T-cell lymphomas (NK/T), three EBV-positive post-transplant lymphoproliferative disease (PTLD)
samples, and two NPC xenografts (Xeno-666 and Xeno-2117).
†Including two NPC xenografts, both carried type A EBV and contained Zp-V3.
‡This sample was co-infected with a variant containing Zp-P.
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RESPONSE
Tong et al. have extended the study
related to BZLF1 polymorphic variants
of Epstein–Barr virus (EBV) to samples
from Hong Kong and Southern China.
This study is of special interest because
it incorporates malignant and nonmalig-
nant samples from regions that are en-
demic for nasopharyngeal carcinoma
(NPC). Their observations both confirm
and contradict several conclusions from
our study (1). First, they provide inde-
pendent confirmation of the existence of
the Zp-P and Zp-V3 variants in another
geographic region. Our earlier observa-
tions suggested that Zp variants segre-
gated strongly by EBV type, with type B
virus exclusively associating with Zp-
V3 and type A virus often associating
with Zp-P. Exceptions were noted in
samples from Far East Asia, which con-
tained type A virus with a Zp-V3 se-
quence, suggesting that type A Zp-V3
may be prevalent in this geographic re-
gion. Tong et al. confirm these findings
and validate the existence and the preva-
lence of the type A Zp-V3 variant in the
Southeastern Asian population.
Type B virus is generally considered
to be more readily inducible than the
type A virus (2). We have speculated
that the association of a virus with ma-
lignant and nonmalignant lesions is in-
fluenced by the lytic potential of the vi-
ral types, which in turn may be dictated
by the variation in Zp. Tong et al. found
a statistically significant association be-
tween type A Zp-V3 and NPC. One pos-
sible interpretation of these observations
would be that a type A Zp-P variant is
more responsive to lytic induction than a
type A Zp-V3 variant. However, addi-
tional regulatory elements beyond Zp
also modulate BZLF1, and the possibil-
ity that variations in these regions occur
between type A Zp-P and type A Zp-V3
needs to be considered.
Several important differences also
arise between our observations (1) and
those of Tong et al. For example, there is
the complete absence of Zp-V4 in their
samples. We identified 53 Zp-V4 vari-
ants among our nonmalignant samples.
It is highly unlikely that these differ-
ences are merely technical. An impor-
tant element in these two studies per-
tains to the origin of the samples. Our
samples from South and North America,
Saudi Arabia, and Japan—all regions
non-endemic for NPC (3)—contained
EBV with a Zp-V4 variant. If indeed the
prevalence of Zp-V4 is geographically
restricted, it raises important epidemio-
logic considerations that may affect the
pathogenesis of EBV-associated malig-
nancies. If the absence of Zp-V4 in tu-
mors reflects lower oncogenic potential,
the diminished prevalence of this strain
in a population endemic for EBV-asso-
ciated malignancies is of notable in-
terest. Additional studies from other
endemic and non-endemic areas are re-
quired to establish these associations.
The apparent mutual exclusivity of
Zp-V4 and Zp-V3 EBV in non-endemic
and endemic populations, respectively,
is intriguing. Given the low levels of
EBV DNA in nonmalignant samples,
the possibility that Zp-V3 and Zp-V4
variants are present at undetectable lev-
els cannot be ruled out. Furthermore, the
identification of other variants—albeit
at low frequency—raises the possibility
that ongoing mutational events may in-
deed play a role in the genesis of such
variations (4).
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